Literature DB >> 23121407

Pre-existing central nervous system lesions negate cytokine requirements for regional experimental autoimmune encephalomyelitis development.

Xin Li1, Jason R Lees.   

Abstract

In region-specific forms of experimental autoimmune encephalomyelitis (EAE), lesion initiation is regulated by T-cell-produced interferon-γ (IFN-γ) resulting in spinal cord disease in the presence of IFN-γ and cerebellar disease in the absence of IFN-γ. Although this role for IFN-γ in regional disease initiation is well defined, little is known about the consequences of previous tissue inflammation on subsequent regional disease, information vital to the development of therapeutics in established disease states. This study addressed the hypothesis that previous establishment of regional EAE would determine subsequent tissue localization of new T-cell invasion and associated symptoms regardless of the presence or absence of IFN-γ production. Serial transfer of optimal or suboptimal doses of encephalitogenic IFN-γ-sufficient or -deficient T-cell lines was used to examine the development of new clinical responses associated with the spinal cord and cerebellum at various times after EAE initiation. Previous inflammation within either cerebellum or spinal cord allowed subsequent T-cell driven inflammation within that tissue regardless of IFN-γ presence. Further, T-cell IFN-γ production after initial lesion formation exacerbated disease within the cerebellum, suggesting that IFN-γ plays different roles at different stages of cerebellar disease. For the spinal cord, IFN-γ-deficient cells (that are ordinarily cerebellum disease initiators) were capable of driving new spinal-cord-associated clinical symptoms more than 60 days after the initial acute EAE resolution. These data suggest that previous inflammation modulates the molecular requirements for new neuroinflammation development.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23121407      PMCID: PMC3573274          DOI: 10.1111/imm.12029

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors.

Authors:  Laura Piccio; Barbara Rossi; Elio Scarpini; Carlo Laudanna; Cinzia Giagulli; Andrew C Issekutz; Dietmar Vestweber; Eugene C Butcher; Gabriela Constantin
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

Review 2.  Three or more routes for leukocyte migration into the central nervous system.

Authors:  Richard M Ransohoff; Pia Kivisäkk; Grahame Kidd
Journal:  Nat Rev Immunol       Date:  2003-07       Impact factor: 53.106

3.  Early prognostic factors for disability in multiple sclerosis, a European multicenter study.

Authors:  T Riise; M Grønning; O Fernández; K Lauer; R Midgard; J M Minderhoud; H Nyland; G Pálffy; S Poser; J A Aarli
Journal:  Acta Neurol Scand       Date:  1992-03       Impact factor: 3.209

4.  ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro.

Authors:  B J Steffen; G Breier; E C Butcher; M Schulz; B Engelhardt
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

5.  IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis.

Authors:  D O Willenborg; S Fordham; C C Bernard; W B Cowden; I A Ramshaw
Journal:  J Immunol       Date:  1996-10-15       Impact factor: 5.422

6.  Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models.

Authors:  T Riise; M Grønning; J A Aarli; H Nyland; J P Larsen; A Edland
Journal:  J Clin Epidemiol       Date:  1988       Impact factor: 6.437

7.  Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system.

Authors:  H S Panitch; R L Hirsch; J Schindler; K P Johnson
Journal:  Neurology       Date:  1987-07       Impact factor: 9.910

8.  Interferon-gamma confers resistance to experimental allergic encephalomyelitis.

Authors:  M Krakowski; T Owens
Journal:  Eur J Immunol       Date:  1996-07       Impact factor: 5.532

9.  Adhesion of lymphocytes to endothelial cells in experimental allergic encephalomyelitis before and after treatment with endotoxin lipopolysaccharide.

Authors:  M Matsuda; N Tsukada; K Miyagi; N Yanagisawa
Journal:  Int Arch Allergy Immunol       Date:  1995-04       Impact factor: 2.749

10.  Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).

Authors:  I A Ferber; S Brocke; C Taylor-Edwards; W Ridgway; C Dinisco; L Steinman; D Dalton; C G Fathman
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

View more
  3 in total

1.  A novel CNS-homing peptide for targeting neuroinflammatory lesions in experimental autoimmune encephalomyelitis.

Authors:  Bodhraj Acharya; Rakeshchandra R Meka; Shivaprasad H Venkatesha; Jason R Lees; Tambet Teesalu; Kamal D Moudgil
Journal:  Mol Cell Probes       Date:  2020-02-05       Impact factor: 2.365

2.  Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor.

Authors:  Shengwen Calvin Li; Lisa May Ling Tachiki; Mustafa H Kabeer; Brent A Dethlefs; Michael J Anthony; William G Loudon
Journal:  Cancer Cell Int       Date:  2014-11-12       Impact factor: 5.722

3.  Experimental autoimmune encephalomyelitis (EAE) up-regulates the mitochondrial activity and manganese superoxide dismutase (MnSOD) in the mouse renal cortex.

Authors:  Balamurugan Packialakshmi; Xiaoming Zhou
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.